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Mechanism of lithium-induced polyuria in the rat. While many studies
have demonstrated a nephrogenic diabetes insipidus syndrome (NDI) with
prolonged lithium (Li) treatment, experiments in the isolated rat papillary
collecting duct have suggested that the defect may be due to a circulating
factor that inhibits the action of arginine vasopressin (AVP). Since
Li-treatment can produce a form of hyperparathyroidism and parathyroid
hormone (PTH) can act as a partial agonist to AVP, in vivo and in vitro
studies were performed on rats made polyuric by daily intraperitoneal
(i.p.) Li (4 mmollkg) treatment. Li-treatment for three weeks produced an
increase in PTH (194 20 compared with 118 18 pg/mI in control rats;
P < 0.01) as well as an increase in the plasma calcium concentration (2.38
0.05 compared with 2.25 0.04mmol/liter; P < 0.05).Clearance studies
were performed on water loaded Li-treated and control rats, and the
defect in urine concentration was only observed with a low physiological
concentration of AVP (10 mU/kg body wt over 5 mm). Maximal urine
osmolality was 328 31 compared with 613 81 mOsm/kg (P < 0.05) in
controls. There was no detectable difference with a prolonged maximal
physiological AVP concentration (10 mU bolus and 50 mU/kg body wt per
hr) and papillary solute concentrations were unchanged. When Li-treated
rats had been parathyroidectomized (PTX), a significant difference in
urine concentration with the low AVP concentration could not be
demonstrated when compared to non-PTX control rats. In the isolated
papillary collecting duct preparation a medium was used that contained
fresh plasma from Li-treated or control rats, both intact and PTX.
Experiments using plasma from Li-treated intact rats produced only a 25.4
5.1% increase in diffusional water permeability with the addition of
AVP (200 jzU!ml) compared to 52.6 9.0% in control rats (P < 0.01).
However, when plasma from Li-treated PTX rats was used, the AVP
induced increase in water permeability (54.7 11.2%) was not signifi-
cantly different from that observed in PTX control rats. These studies
show that the NDI-like defect in Li-treatment is small and easily overcome
by higher concentrations of AVP and suggests that the concentration
defect is at least in part due to increased circulating levels of PTH acting
as a partial agonist to AVP and thereby inhibiting its hydroosmotic action.
It is accepted that the diabetes-insipidus-like syndrome induced
by prolonged lithium (Li) administration is due to a resistance of
the collecting duct cells to the antidiuretic action of vasopressin
(AVP) [1]. However, a series of experiments in the isolated rat
papillary collecting duct did not support this hypothesis [21. AVP
induced increases in water permeability were not reduced by the
presence of bath Li concentrations similar to that found in
papillary tissue and urine of polyuric Li-treated rats [3, 4].
Furthermore, the addition of Li to the perfusate as well as the
bath in papillary collecting ducts from Li-treated polyuric rats also
failed to demonstrate any inhibitory effect of Li on AVP action.
Bentley and Wasserman [5] were also unable to demonstrate any
effect of Li on AVP induced osmotic water transport in the toad
bladder, although other studies using this model, which is not
analogous to the mammalian collecting duct, have demonstrated
inhibitory effects of Li on AVP stimulated water flow [6—81.
However, in vivo micropuncture studies in Li-treated rats have
also failed to demonstrate a depressant action of Li on AVP
induced distal water reabsorption [9, 10]. Clearly there are
significant contradictions in the available experimental data.
There are two ways to reconcile an apparent paradox in the rat
where clearance studies support a nephrogenic diabetes insipidus-
like syndrome, yet in vivo and in vitro micropuncture studies do
not. One possibility is that Li interferes with the ability of the
kidney to produce a maximal corticopapillary concentration gra-
dient. Unfortunately, measurements of this gradient have again
produced conflicting results, with reports of normal [3, 11, 12] and
reduced [4, 7, 13] papillary solute concentrations with Li-treat-
ment. Since these experiments were performed comparing poly-
uric Li animals with non-polyuric controls, comparing solute
gradients during comparable water diuresis in both groups would
be more appropriate.
Another possibility is that Li-treatment produces a circulating
factor that inhibits the response of the collecting duct to AVP or
inhibits the release of a facilitatory factor to AVP. Such a
possibility is supported by in vitro studies [14, 15] where plasma
from Li-treated rats was added to the bath and compared with
artificial medium. Evidence that Li-treatment produces a form of
primary hyperparathyroidism [16—19], combined with evidence
that parathyroid hormone (PTH) can act as a partial agonist to
AVP in vivo and in vitro [20, 21] suggested that PTH could be a
cause of the nephrogenic diabetes insipidus (NDI) syndrome.
Consequently, the effect of high and low physiological concentra-
tions of AVP on urine concentration in chronic Li-treated and
control animals was evaluated, both in the presence and absence
of their parathyroid glands. Both Li-treated and control animals
were studied in a comparable diuretic state. Papillary solute
concentrations were also measured. In addition, the effect of AVP
on isolated papillary collecting duct water permeability was stud-
ied using a medium composed of plasma from parathyroidecto-
mized (PTX) or intact Li-treated and control rats.
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Experiments were conducted on adult male and female Wistar
rats weighing between 250 and 300 g housed in an air-conditioned
room (21° to 23°C). One group of rats was fed a normal laboratory
diet and allowed water ad libitum (control group) while another
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group was, in addition, treated with daily i.p. injections of LiC1 (4
mmol/kg body wt) for at least 21 days to produce a marked
polyuria [3]. In the unanesthetized rat, such a protocol produces
a urine output of approximately 42 compared to 3 mI/100 g body
wt/day [19]. On the day of the clearance or micropuncture studies,
Li-treated rats were given their daily i.p. injection one hour before
anesthesia or decapitation while control rats were given an
equimolar injection of NaCl,
In vivo clearance studies
All rats were anesthetized with mactin (100 mg/kg i.p.) and
placed on a heated table to maintain body temperature at 37°C.
Following tracheotomy, animals were infused via a jugular vein
catheter (PE5O) with a 75 mmol NaCI and 1.75% dextrose
solution at a rate of 6% body wt over a 20 minutes period. This
rate was then reduced to a rate of 12 ml/hr for a further 60
minutes. A 15-minute urine collection was then performed and a
midpoint blood sample collected. AVP was then administered via
the jugular catheter as a bolus injection of 10 mU/kg body wt and
continued at a rate of 50 mU/kg body wt/hr (maximal AVP
concentration) or as a bolus dose of 10 mU/kg body wt over five
minutes without continued infusion (low AVP concentration).
The former concentration has been demonstrated to produce a
maximal antidiuretic effect in this preparation [21], while the
latter and smaller dose has been employed in an earlier published
study that showed an inhibitory effect of Li on water transport [3].
Three more 15-minute urine collections were then performed as
well as midpoint blood samples between the first and second as
well as the second and third urine collections.
In some Li-treated and control rats, PTX was also performed
immediately after tracheotomy by identification of both glands
under stereomicroscopic vision, splitting the fascial covering and
avulsing both glands with forceps. This cleanly removed both
glands but was followed by electrocautery of the resulting cavities
in the thyroid gland. To ensure degradation of any residual PTH,
clearance experiments were commenced 120, not 60, minutes
later.
In an additional series of experiments, papillae were removed
from both anesthetized control and Li-treated diuretic rats imme-
diately before the administration of AVP and the papillary solute
concentration was measured by the method of Gardner and
Vierling [22].
In vitro micropuncture studies
Normal rats were given 10 ml water i.p. and decapitated one
hour later. Renal papillae were rapidly isolated and incubated for
one hour at 37°C before experimentation in a modified Krebs-
Ringer solution (NaCl 150, K2HPO4 2.5, MgSO4 1.2, CaCl2 1,
urea 200, dextrose 5.5 mmol and calf serum 5% by volume and
vigorously bubbled with 95% 02 with pH adjusted to 7.4). Papillae
were then set up in a bath for micropuncture as previously
described [23]. The bath contained a 1 to 1 mixture of a
modification of the above Krebs-Ringer solution (NaCI 160, KC1
5, MgC12 2, urea 400 mmol) and plasma taken from intact or PTX
Li-treated and untreated rats. Half of these rats had been
anesthetized the evening before the experiments with sodium
pentothal and had their parathyroid glands removed while the
others had sham operations. The next morning all animals were
anesthetized, blood collected from the abdominal aorta, placed in
Table 1. Plasma parameters in lithium-treated and control rats
Control
(N = 8)
Li-treated
(N = 8)
P
valuea
PTHpg/mL 108 18 194 20 0.01
Plasma Ca mm/liter 2.25 0.04 2.38 0.05 0.05
UF Ca mm/liter 1.36 0.04 1.49 0.04 0.05
Plasma Li mm/liter — 1.21 0.09 —
Hematocrit % 40 1 39 1 NS
Abbreviation is: UF, ultrafilterable.
Statistical significance Li vs. control
heparinized tubes and centrifuged, and the plasma mixed with the
artificial solution for immediate use in the micropuncture studies.
Experiments were then performed to determine the diffusional
water permeability of superficial papillary collecting ducts before
and after the addition a maximal concentration of AVP (200
J.LU/ml) for this preparation [24]. Collecting ducts were punctured
and perfused using a perfusion solution (NaCl 150, K2HPO4 2.5,
MgSO4 1.2, CaCl2 1.0, urea 200 mmol) having the same osmolar-
ity as the medium and containing tritiated water. Table 1 demon-
strates the concentrations of solutes in the perfusion solution and
final medium. The same collecting ducts were then punctured at
a distal site and duplicate collections made. AVP was then added
and distal collections were repeated. The micropuncturist was
unaware of the origin of the medium used. The diffusional water
permeability was calculated from the formula [25] P = Vi/A X Ln
(C1/C0) where V is the perfusion rate (30 nI/mm), A is the luminal
surface area, C1 the isotope counts in the perfusate and C0 the
isotope counts in the collected samples.
Analysis
[51Cr]EDTA levels for the measurement of glomerular filtra-
tion rate were counted on a gamma counter (Packard Instrument
Co.). The mean arterial pressure was monitored using a pressure
transducer (Gould-Stratham) and a polygraph (Grass). Sodium,
potassium and lithium concentrations were measured on a flame
photometer (Corning); calcium and magnesium were measured
by an atomic absorption spectrophotometer (Varian), and phos-
phate by a colorimetric method [26]. Plasma calcium and magne-
sium ultrafiltrates were obtained using ultrafiltration cones
(Amicon). Urine and plasma osmolalities were measured on a
micro-osmometer (Wescor Advance Instruments), and tritiated
water radioactivity was determined in a liquid scintillation spec-
trometer (Packard Instrument Co.). Plasma PTH concentrations
were performed using a radioimmunoassay [27].
Materials
Arginine vasopressin (350 U/mg) was purchased from Sigma
Co., and bovine serum albumin from Commonwealth Serum
Laboratories.
Analysis
All results are expressed as means SEM. Statistical analysis
was performed using an analysis of variance and a t-test adapted
for multiple comparisons [28].
Carney et al: Lithium-induced polyuria 379
Table 2. Clearance data and papillary tissue analysis from control and
lithium treated anesthetized rats during a water diuresis induced by a
075 mmol NaCI and 1.75% dextrose solution
Lithium-
Control
(N = 7)
treated
(N = 7)
P
value*
Urine flow p1/mm 164 18 155 16 NS
Uom (mOsm/kgH2O 114 6 116 7 NS
mOsm/kg H20 289 7 282 4 NS
Co.m mOsml/kg/min 65 5 64 4 NS
CH20 jd/min 99 6 92 5 NS
GFR mI/mm 2.8 0.2 2.6 0.3 NS
mmol/liter — 1.2 0.2 —
Water content % tissue wet wt 87 1 88 1 NS
Na4 content mmol/kg II2O 167 11 157 10 NS
K content mmol/kg 1120 47 2 50 4 NS
Li content mmol/kg JI20 — 8 1 —
Total solutes mmol/kg 2730 237 2736 259 NS
Abbreviations are: GFR, glomerular filtration rate; U, urine; P, plasma;
C, clearance; C1120, free water clearance.
a Values P > 0.05 were considered nonsignificant (NS).
Results
Effect of chronic Li-treatment on calcium metabolism
Li-treated rats had a significantly elevated PTH concentration
when compared to non-treated animals (194 20 compared to
118 18 pg/mI; P < 0.01), while the plasma total and ionized
calcium concentrations were elevated: 2.38 0.05 and 1.49 0.04
compared to 2.25 0.04 and 1.36 0.04 mmol/liter (P < 0.05) in
eight Li-treated and eight control rats killed two hours after the
morning i.p. injection, respectively (Table 1). In the Li-group the
Li concentration was 1.21 0.09 mmol/liter.
Clearance studies
Water diuretic control and Li-treated rats failed to demonstrate
any significant difference in glomerular filtration rate, urine flow,
and solute and water excretion (Table 2). Also, the papillary
solute concentrations measured were not significantly different.
When a maximal concentration of AVP (10 mU/kg stat and 50
mU/kg/hr) was infused into water diuretic anesthetized Li-treated
rats, no significant difference in urine flow or osmolality was
observed when the response was compared to the control group
(Table 3). AVP produced a prompt and significant increase in
urine osmolality in both groups: 1020 107 compared with 924
115 mOsm/kg, respectively, during the final collection period.
However, with the administration of a low concentration of AVP
(10 mU/kg infused for only 5 mm), the previously described
inhibitory effect of Li-treatment in this preparation was noted.
While this concentration of AVP still produced a reduction in
urine flow and an increase in urine osmolality in the Li-treated
group, this effect was significantly less than in the control group in
the first two but not the final collection period.
In a further series of experiments using the low concentration
brief AVP infusion protocol (10 mU/kg over 5 mm), the effects of
prior PTX was compared in control and Li-treated animals.
Again, in the intact groups, Li-treatment inhibited the action of
AVP (Fig. 1). However, PTX abolished this inhibitory effect and
urine osmolality and flow was not significantly different in the
control and Li-treated rats. Parathyroid glands were also larger in
the Li-treated animals on microscopy and weight. Weight ratio
between Li-treated and control rats was 1.41.
Micropuncture studies
The increase in the diffusional water permeability in perfused
superficial collecting ducts of control intact rats with a maximal
concentration of AVP (200 .tU/ml) was 52.6 9.0% (P < 0.01)
the diffusional water permeability increasing from 4.68 0.19 to
7.14 0.55 gm/sec (Fig. 2). Plasma from PTX rats did not
significantly alter the increase produced by AVP (51.3 11.8%).
However, the increase in water permeability with AVP was
significantly depressed in medium composed of plasma from
intact Li-treated rats with only a 25.4 5.1% rise. However, when
the medium used was from plasma of PTX Li-treated rats, the
water permeability response was much greater (54.7 11.2%):
4.75 0.35 tm/sec pre-AVP and 7.35 0.51 j.m/sec post-AVP.
This increase was not significantly different from control PTX rats.
The relative concentrations of electrolytes in the bathing medium
as well as perfusate for this series of experiments is detailed in
Table 4. In particular, the mean calcium concentration in the Li
medium was not significantly different from that measured in the
control group.
Discussion
A water diuretic model was chosen to inhibit endogenous AVP
release and dextrose was used because increasing plasma concen-
trations do not stimulate AVP release [29]. Because of the chosen
experimental model, the animals required anesthesia, however,
Shirley, Zearde and Walter [301 have demonstrated that renal
function and electrolyte transport in mactin anesthetized rats is
similar to that measured in unstressed conscious rats. Acute PTX
was used to minimise receptor changes from hypocalcemia.
Concentrations of AVP used were based on previous studies in
this model [21]; however, because of our inability to detect any
inhibitory effect of Li-treatment on AVP action in the intact
animal (several AVP concentrations were used although the
results are not presented), we finally followed the original proto-
col of Forrest et al [3] where a relatively low physiological
concentration of AVP was administered as a bolus rather than a
prolonged infusion. In these experiments, Li-treatment produced
a form of hyperparathyroidism with a 65% increase in the plasma
PTH concentration at the time of testing, similar to that previ-
ously observed in human and rat [16, 17]. The previously de-
scribed NDI syndrome was again demonstrated in anesthetized
Li-treated rats [3, 6]; however, this inhibitory effect of Li-treat-
ment on AVP action in the collecting duct was only apparent with
a low AVP concentration infused over a short time period (low)
and was easily overcome with a higher (maximal) and sustained
concentration. Thus, the NDI syndrome has been confirmed in
vivo. Such a syndrome is unlikely to be due to a reduced papillary
solute concentration gradient since water loaded polyuric control
rats had a similar gradient when compared with Li treated rats.
Removal of the parathyroid glands appeared to reverse the
concentration defect in the Li rats, and this reversal was also
demonstrated in the isolated papillary collecting duct where an
artificial medium and plasma mix from PTX Li-treated rats
allowed a normal diffusional water permeability response to AVP.
These results therefore support the proposition that an increased
plasma concentration of PTH is the circulating factor that inhibits
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Table 3. Comparison between a constant maximal infusion and a brief minimal infusion of AVP in control and lithium treated anesthetized rats
Pre-AVP Post-AVP
Control Li
Cotlection 1 Collection 2 Colle
Control
ction 3
LiControl Li Control Li
Maximal AVP
10 mU/kg stat + 50 mU/kg/hr (12) (11) (12) (ii) (12) (11) (12) (11)
Urine flow 1.dlmin 163 22 149 7 56 28 61 16 45 11 38 9 38 15 29 7
U0,,, mOsm/kg H20 109 7 108 5 496 71 414 50 738 98 696 81 924 115 1020 107
Minimal AVP
10 mU/kg over5 mm
Urine flow p1/mm
(8) (8)
154 18 149 21 (8)39 6 (8)58 7" (8) (8)82 18 129 17h (8)161 23 (8)183 15
U0,,, mOsmlkg -2O 110 7 112 7 411 28 328 31b 613 81 231 53" 315 57 137 18
"Numbers in parenthesis denotes number of rats in group; h P < 0.05
the action of AVP. Thus PTH acts as a partial agonist to AVP,
having a weak AVP-like action on water transport at high
concentrations yet inhibiting the effect of low concentrations of
AVP. This inhibitosy effect can be overcome by higher concen-
trations of dDAVP, as has been demonstrated in vitro [20] and in
vivo [21]. Christensen [31] has also demonstrated in rats that
higher doses of AVP can overcome the NDI effect of Li-
treatment, thus supporting our proposition. These experiments
therefore offer an explanation for the apparent paradox where in
vivo experiments have demonstrated a defect in concentration [3,
6], while in vitro experiments in artificial medium have not [2]. In
support of such an hypothesis, calcitonin, another polypeptide
hormone with similar distal tubule transport functions to PTH has
also been found to act as a partial agonist to AVP both in vivo and
in vitro and over a similar concentration range [32, 33]. In another
target tissue, PTH has been found to inhibit AVP induced
vascular smooth muscle contraction [34], further supporting an
interaction of these related polypeptide hormones.
It is difficult to compare the concentrations of hormone neces-
sary to produce such a specificity 'spill over' effect in in vivo and in
vitro conditions. In the isolated collecting duct, 50 ng/ml of PTH
in the medium produced a 20% increase in diffusional water
permeability, and a 10% increase at 5 ng/ml was not significant
[20]. The level of PTH measured in our Li-treated rats was 0.194
ng/ml. Nevertheless, in other comparisons of in vivo and in vitro
Table 4. Solute concentrations in final medium derived from normal
control or lithium treated rats and in the artificial collecting
duct perfusate
Control
Li medium
(N = 12)
medium
(N = 13) Perfusate
Na mmol/liter 147 3 148 2 150
K mmol/liter 4.90 0.3 5.0 0.5 5.0
Cl mmol/liter 142 6 140 5 152
Ca mmol/liter 1.19 0.09 1.14 0.07 1.0
Mg mmol/liter 1.29 0.08 1.26 0.08 1.20
Li mmol/liter 0.61 0.5 — —
P04 mmol/liter 0.69 0.10 0.78 0.08 2.50
Urea mmol/liter 202 15 203 18 200
Osmolality mOsm/kg
"(Ca mmol/liter)
519 42
(0.96 0.11)
520 31
(0.92 0.12)
513
"Denotes number of experiments where solutes measuredbFinal calcium concentration in the medium made with plasma from
PTX rats
systems, for example, using AVP, hormone concentrations re-
quired to produce an in vitro physiological effect are often 10 to
100 times higher than that required in in vivo systems [24]. In a
recent study, 2 tg/kg body wt rat PTH [1—34]Ihr infused into aduJt
rats which is a maximal phosphaturic concentration in the model
used, produced a sudden although brief (30 to 40 mm) 35% fall in
urine excretion [21]. These observations lend support to the
proposition that the effect of PTH on AVP receptors can occur at
high physiological rather than pharmacological concentrations of
hormone.
Another possible explanation for the role of Li-induced hyper-
parathyroidism in inhibiting the action of AVP is the hypercalce-
mia produced by Li-treatment. In the in vivo studies, a small but
significant increase in plasma calcium was measured. However, in
the in vitro studies where a mixture of plasma and artificial
medium was used, these differences were very small and not
statistically significant. Therefore it seems most unlikely that
calcium could be the elusive circulating factor. In a recent review
[34] it was suggested that hypercalcemia was unlikely to impair the
hydroosmotic action of AVP. Other workers have in fact demon-
strated such a defect [35] but only at very high calcium concen-
trations, and such a defect could not be overcome by higher
concentrations of AVP.
The observation in many studies of a corresponding inhibition
of the adenylate cyclase-cAMP system has always supported the
assumption that Li-treatment produces a NDI syndrome. How-
ever, several workers have failed to demonstrate a close associa-
tion between this system and the corresponding physiological
event, both in AVP-induced water transport [2, 24] and in other
systems [36—38]. More recently Anger et a! [39] couldn't demon-
strate any inhibitory effect of Li on cAMP generation in cultured
rat inner medullary collecting tubule cells with 5 miu Li, a
concentration that would reasonably be expected within the
medulla. However, very high concentrations of 10 m or more
acutely inhibited cAMP generation while prolonged exposure
enhanced cAMP formation. To further underline our lack of
understanding of the effect of Li on this complex system, even in
studies where Li was found to inhibit the generation of cAMP, the
proposed sites of action were contradictory [3, 6, 40].
An inhibitory effect of Li on proximal tubule function [10] could
theoretically inhibit urine concentration and could partly explain
the contradictory in vivo and in vitro data. However, this is unlikely
to be important since there is clearly a defect in AVP action and
400
200
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Fig. 1. Changes in urine osmolalily (upper
panel) and urine volume (lower panel) with time
in control () and Li-treated (0) intact and PTX
anesthetized rats using the minimal A VP
concentration (10 mU/kg body wt over 5 mm).
Each point denotes mean SEM of between 9
and 18 samples. *Denotes value significantly
(P < 0.01) different from control (t-test).
this can be overcome with modest concentrations of AVP in the in
vivo situation.
A recent study has demonstrated that Li-treatment down
regulates aquaporin-2 water channel expression in rat renal
medulla [41]. While such an observation appears to support the
notion that Li does directly alter tubule water transport, an
alternative explanation also fits many of the experimental obser-
vations. Since Li-treatment produces a central form of polydipsia
and is therefore responsible for at least part of the 670% increase
in urine output measured in these rats, a fall in circulating AVP
would be expected, although this was not measured. Such a
reduction would be a powerful stimulus for reduced aquaporin
expression. If Li toxicity was the stimulus for a fall in aquaporin
expression, why would concomitant thirsting markedly increase
aquaporin expression? Again, this may have been due to an
increase in circulating AVP. Certainly the plasma osmolality was
significantly higher in rats treated with Li for 34 days with thirsting
for two days compared with animals not thirsted but treated for 35
days with Li (397 8 compared with 314 5 mOsm/kg H20).
Concomitant dDAVP also produced a partial response and
supports our results.
In summary, these studies suggest that Li-treatment does
produce a modest form of NDI and that this defect is at least in
part due to a state of hyperparathyroidism whereby excessive
circulating levels of PTH act as a partial agonist to the hydroos-
motic action of AVP. This inhibitory effect is easily overcome by
higher but physiological doses of AVP. While the clinical situation
of patients with marked polyuria might suggest that the defect in
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Fig. 2. Percentage increase in diJJhsional water permeability with AVP (200
p.U/ml) in isolated rat papilla,y collecting duct. Medium composed of
plasma from control (Lii) or Li-treated () intact or PTX rats. Each bar
denotes mean SEM of total number of samples, denoted at the bottom
of the bars.
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